At a glance
- Originator Aventis
- Class Antihyperlipidaemics
- Mechanism of Action Cholesterol synthesis inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Hypercholesterolaemia
Most Recent Events
- 04 Aug 2003 Discontinued - Preclinical for Hypercholesterolaemia in USA (unspecified route)
- 04 Aug 1999 No-Development-Reported for Hypercholesterolaemia in USA (Unknown route)
- 21 Dec 1994 Preclinical development for Hypercholesterolaemia in USA (Unknown route)